Indications |
Oral Locally advanced or metastatic non small cell lung carcinoma Adult: 250 mg once daily. Special Populations: For patients on potent CYP3A4 inducer: 500 mg daily if tolerated. For patients with poorly tolerated diarrhoea or skin ADR: Up to 14 days therapy interruption followed by reinstatement of the 250 mg daily dose. |
Contraindications |
Hypersensitivity; pregnancy; lactation. |
Warnings / Precautions |
Severe renal or hepatic impairment; idiopathic pulmonary fibrosis; acute onset or worsening of pulmonary or eye symptoms. Monitor hepatic function periodically. Monitor regularly for changes in prothrombin time or International Normalized Ratio in patients on warfarin treatment. |
Adverse Reactions |
GI disturbances, anorexia; hepatotoxicity; rash, acne, dry skin, skin blemishes; weakness; peripheral oedema; amblyopia; cough, dyspnoea; conjunctivitis; mouth ulceration; eye irritation, corneal membrane sloughing, ocular ischaemia or haemorrhage; pancreatitis; toxic epidermal necrolysis; erythema multiforme; hypersensitivity reactions. Potentially Fatal: Interstitial lung disease. |
Drug Interactions |
CYP3A4 inducers and H2-receptor antagonists decrease effectiveness of gefitinib. CYP3A4 inhibitors increase efficacy of gefitinib. Increased metoprolol concentrations. INR elevations and/or bleeding events with warfarin. Increased plasma concentrations of metoprolol when used with gefitinib. See Below for More gefitinib Drug Interactions |
Mechanism of Actions |
Gefitinib is an anilinoquinazoline. Gefitinib generally attaches to epidermal growth factor receptors (EGFRs), thereby blocking the attachment of EGF and the activation of tyrosine kinase. It is used as monotherapy for the treatment of locally advanced or metastatic nonsmall cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. |
Administration |
Film-coated tab: May be taken with or without food. (May also be dispersed in ½ glass of plain, non-carbonated water. No other liqds should be used. Drop the tab in water & stir w/o crushing until it disperses (approx 10 min). Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via NG tube.) |
ATC Classification |
L01XE02 - gefitinib ; Belongs to the class of protein kinase inhibitors, other antineoplastic agents. Used in the treatment of cancer. |
Available As |
|
Gefitinib
Post Review about Gefitinib Click here to cancel reply.
Gefitinib Containing Brands
Gefitinib is used in following diseases
Drug - Drug Interactions of Gefitinib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.